Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
about
Breast carcinoma in situ: risk factors and screening patternsReproductive and hormonal risk factors of breast cancer: a historical perspective.Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancerCurrent and potential future drug treatments for osteoporosis.Ethnic differences in hormone replacement prescribing patternsThe impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers.Discussion of hormone replacement therapy between physicians and their patients.Observation and experiment on the cusp of collaboration: a parallel examination of clinical pharmacology and pharmacoepidemiology.Migraine, menopause and hormonal replacement therapy.Breast cancer hypothesis: a single cause for the majority of cases.Chains of evidence, mosaics of data: does estrogen 'cause' breast cancer? How would we know?Risk factors of breast cancer: a systematic review and meta-analysis.Breast cancer and hormone replacement therapy: putting the risk into perspective.Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysisPrevious oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women.Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.Current breast cancer risks of hormone replacement therapy in postmenopausal women.Women's attitudes towards menopause and hormone replacement therapy.Postmenopausal hormone therapy and the risk of breast cancer in Norway.Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis.Lipoprotein disorders in women: which women are the best candidates for hormone replacement therapy?Controversies surrounding estrogen use in postmenopausal women.Hormone replacement therapy and the risk of reproductive cancers.Use of hormone replacement therapy. May depend on whether the menopause is regarded as physiological or pathological.Use of hormone replacement therapy. Authors gave distorted view through selective citation.Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast.Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women.The 'cause' of my cancer, beliefs about cause among breast cancer patients and survivors who do and do not seek IO care.Improving family ties: an examination of the complementary disciplines of pharmacoepidemiology and clinical pharmacology.Postmenopausal hormone therapy and ductal carcinoma in situ: a population-based case-control study.Combined oral estradiol valerate-norethisterone treatment over three years in postmenopausal women. 1. Clinical aspects and endometrial histology.Impact of hormone replacement therapy use on mammographic screening outcomes
P2860
Q28209206-6598D25E-D834-4FA5-9A09-7E70F7569207Q30234506-EFA0E12A-B2EE-478F-8855-35599144A8C8Q30498819-5536588E-A900-4601-A7D7-AD0B3ABB0E66Q33579316-4C0B365C-2F49-4B1A-BEF3-841CDA2EC283Q33778878-EF4CF097-048E-4BEF-8231-9D75C6FAB381Q33814554-A3169141-DE54-4ED8-AA7F-830989E31E13Q34008254-33F3A4DE-E4F0-496B-8DA2-9CDC28C998CFQ34024124-5F126F26-3869-4E30-86C3-96C0BDB3E88BQ34039852-E84CDEDC-ABFF-4BE0-B2ED-8219E48E7735Q34057720-84B1554B-83ED-4DF1-B16A-DD88DC10F7E4Q34285969-C974E30D-2B54-4AEB-8F36-166764629052Q34346863-018B2286-2C97-48D9-9A0D-2C77529117C6Q34847541-58CB24C3-140B-4471-BBF0-5FD1C1EC9440Q35608346-3520D9B0-464C-42DB-9A1E-21C98CEF008EQ35990596-7F5291F4-E398-417D-AF1E-CA8DC0421B14Q36670890-6AE86F6F-8414-4E33-AB35-3C63406440F5Q36675379-22158D02-85BF-4E21-918A-769FBE974F72Q39434211-D8211F8D-0FA1-4D80-91A1-0E3FA81F031BQ40626144-28238065-0E35-479A-AF3B-DC84B3C556F2Q40928631-107F0BF5-00CD-42BB-BD78-46D05AAF3530Q41316319-D33CAC86-649A-4CD1-B203-CD15BFCF8A3AQ41498790-7F35F54E-DB2C-40D0-A525-805E7C9F2E15Q41528361-81017FB2-7C26-4D0A-B2B0-1D19C4F401EFQ43005738-E5DEDA66-A00D-47A9-89CB-B4CFCD36771FQ43189536-851ADAA0-27A2-4FAA-856E-75E29E507073Q43836825-41E1729E-B66B-4E39-B6DD-5AF33A0B2F45Q46612204-E5FE24D4-4839-45D8-8BB2-633F18D5EAE2Q50283276-63883E3C-A7C2-4D8C-A47D-7370A1A878D8Q52932431-3DFBF388-E62A-48D2-BFFB-3746D76688CFQ53667640-C58CFDFF-1124-405A-8A43-5EE9BEEE761EQ53953668-1DF2637B-0069-4101-B062-FC4CEEBCD0ACQ57586245-04EF94AD-4C3F-4B8A-B8FF-4A718AFBD668
P2860
Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Combined estrogen and progesti ...... t cancer in middle-aged women.
@en
type
label
Combined estrogen and progesti ...... t cancer in middle-aged women.
@en
prefLabel
Combined estrogen and progesti ...... t cancer in middle-aged women.
@en
P2093
P1476
Combined estrogen and progesti ...... t cancer in middle-aged women.
@en
P2093
J L Stanford
J R Daling
M A Rossing
P304
P356
10.1001/JAMA.1995.03530020055032
P407
P577
1995-07-01T00:00:00Z